Skip to content
2000
Volume 7, Issue 10
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Depsipeptide (FK228), a new histone deacetylase inhibitor, has been recently introduced into clinical trials. This agent shows interesting metabolic properties, novel mechanism of action, and is undergoing phase I-II clinical studies in hematopoietic malignancies and solid tumors. Mechanism of action, pharmacokinetics and anticancer activity of depsipeptide is the subject of this review.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/138955707782110178
2007-10-01
2025-01-17
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/138955707782110178
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test